Effectiveness And Safety Of Glucagon-like Peptide 1 Agonist In Treatment Of Polycystic Ovary Syndrome:A Meta-analysis

Objective:Performing the meta analysis about effectiveness and safety of treatment of glucagon-like peptide 1 agonist on polycystic ovary syndrome.Method:Using the subject term,keyword and any word search weipu database,Wangfang database,Pubmed,CBM,CNKI,Cochrance on the computer.retrieval time is from inception to December,10,2019,screening literature and extracting date according to inclusion and exclusion criteria.the meta analysis was carried out by the RevMan5.3 system after the data were extracted according to the quality evaluation of the evaluation system of Cochrane Handbook.Results:A total of 13 randomized controlled trial(RCT)included in the meta analysis by final screening.the results indicate:the experimental group in reducing Body-mass index(BMI),weight,insulin-resistance-index(HOMA-IR),fasting-plasma-glucose(FPG),glycosylated hemoglobin(HAb1C),low-density lipoprotein cholestero(LDL-C),waist circumference,improving sex hormone binding globulin(SHBG),ovulation and pregnancy were better than that in control group,there is significant difference between the two groups.In terms of reducing testosterone,triglyceride(TG),systolic pressure(SBP),diastolic-blood-pressure(DBP),improming-luteinizing-hormone(LH),follicle-stimulating hormone(FSH),there is no statistically significant difference between the two groups.In terms of adverse reactions,there is statistically significant difference between the experimental group in occurrence of the gastrointestinal adverse events.and there is no significant difference between the two groups in the occurrence of hypoglycemia events(the detail please follow the text).Conclusion:Glucagon-like peptide-1 receptor agonist can reduce the patient's BMI and HOMA-IR,plays a positive role to improve glucolipid metabolic disorder.It also promote the patient ovulation and the probability of pregnancy.Glucagon-like peptide-1 receptor agonist does not increase the risk of hypoglycemia events,but in gastrointestinal adverse events may have a greater risk.Overall efficacy and safety were satisfactory.